A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20μg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20μg and desogestrel 150μg

Treatments in Endocrinology

Volumn 5, Issue 2, 2006, Pages 115-121

  Gruber, Doris M ^a   Huber, Johannes C ^a   Melis, Gian Benedetto ^b   Stagg, Caroline ^c   Parke, Susanne ^d   Marr, Joachim ^d  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Pulteney Practice   (United Kingdom)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; YASMINELLE;

ACNE; ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LOW DRUG DOSE; MENORRHAGIA; MENTAL INSTABILITY; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SMOKING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; CHEMICALLY INDUCED; DRUG EFFECTS; MENSTRUAL CYCLE; METRORRHAGIA; UTERUS BLEEDING;

CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; HUMANS; MENSTRUAL CYCLE; METRORRHAGIA; UTERINE HEMORRHAGE;

EID: 33645086136     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605020-00005     Document Type: Article

References (14)

1. Hatcher RA, Guillebaud J. The pill: combined oral contraceptives. In: Hatcher RA, Trussell J, Stewart F, editors. Contraceptive technology. 17th rev. ed. New York: Ardent Media Inc., 1998: 405-66
2. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000 Jun; 5 (2): 124-34
3. Lammers P, op ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70 (6): 497-500
4. Kirkman RJ, Pedersen JH, Fioretti P, et al. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception 1994 Jan; 49 (1): 33-46
5. Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms: North American Levonorgestrel Study Group (NALSG). Contraception 1997 Mar; 55 (3): 139-44
6. Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse): North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 2): 39-44
7. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993 Sep; 100 (9): 832-8
8. Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999 Nov; 60 (5): 269-74
9. An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive: the Mircette Study Group. Am J Obstet Gynecol 1998 Jul; 179 (1): S2-8
10. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997 Mar; 55 (3): 131-7
11. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000 Mar; 5 (1): 25-34
12. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3mg drospirenone. Contraception 2004 Sep; 70 (3): 191-8
13. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003 Mar; 8 (1): 37-51
14. Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003 Feb; 48 (2): 79-85